Chemopreventive dietary compounds, such as flavonols, may inhibit colorectal carcinogenesis partly by altering cytokine expression and attenuating inflammation. Single nucleotide polymorphisms (SNPs) in the promoter regions of genes encoding cytokines may influence flavonolinduced changes in cytokine expression and consequently cancer risk. Using logistic regression, we estimated odds ratios (OR) and 95% confidence intervals (CI) for the association between SNPs of interleukin (IL)-1b, 6, 8, and 10 alone or combined with flavonol intake or serum IL concentration changes, and adenoma recurrence in 808 participants from the intervention arm of the Polyp Prevention Trial, a 4-year intervention study evaluating the effectiveness of a low-fat, high-fiber, high-fruit and vegetable diet on adenoma recurrence. Overall, SNPs in genes encoding IL-1b, 6, 8, and 10 were not associated with their corresponding serum concentrations or adenoma recurrence. However, individuals homozygous for IL-10 -592 C (OR = 2.23, 95% CI: 1.07-4.66, P interaction = 0.03) or IL-10 -819 C (OR = 2.18, 95% CI: 1.05-4.51, P interaction = 0.05) had an elevated risk of high-risk adenoma recurrence when their serum IL-10 concentrations increased during the trial. In addition, IL-6 -174 GG in combination with above median flavonol intake (OR = 0.14, 95% CI: 0.03-0.66) or with decreased IL-6 concentrations (OR = 0.14, 95% CI: 0.03-0.65) reduced the risk of advanced adenoma recurrence, although the interaction term was not statistically significant. In conclusion, our results suggest that IL SNPs, in combination with a flavonol-rich diet or decreased serum IL, may lower the risk of adenoma recurrence.
Introduction
Flavonols are a group of bioactive polyphenols that are abundant in some fruits, vegetables, and tea (Chun et al., 2007; Bobe et al., 2008) . In the US, the median flavonol intake is estimated to be approximately 10-12 mg/day with a range between 0 and 40 mg (Peterson JJ, personal communication). We reported that daily consumption of dietary flavonols above 30 mg decreases the risk of advanced and high-risk colorectal adenoma recurrence (Bobe et al., 2010a) . Flavonols may impede growth of colorectal neoplasms by their antioxidative (Wang et al., 2006) , antimutagenic (Gupta et al., 2010a,) , antiproliferative (Kim et al., 2005) , anti-inflammatory (Chun et al., 2008; Boots et al., 2009; Egert et al., 2010) , and anti-cell transformation properties (Lee et al., 2008) as well as by inducing apoptosis (Jeong et al., 2009) and inhibiting matrix metalloproteinases and angiogenesis (Luo et al., 2009; Zhang and Zhang, 2009) . We are especially interested in the anti-inflammatory properties of flavonols for cancer prevention, as flavonols may attenuate the secretion of the proinflammatory and procarcinogenic cytokines interleukin (IL)-1b, 6, 8 (Krelin et al., 2007; Lin and Karin, 2007; Waugh and Wilson, 2008; Boots et al., 2009; Grivennikov et al., 2009; Okoko and Oruambo, 2009 ) and inhibit the secretion of the pro-and anticarcinogenic IL-10 (Sturlan et al., 2001; Lin and Karin, 2007) .
We reported that increases in serum IL-1b, IL-6, and IL-10 are potential indicators of advanced adenoma recurrence; moreover, that a decrease in these serum cytokines in conjunction with flavonol consumption above 30 mg/day indicated an even lower risk of advanced adenoma recurrence (Bobe et al., 2010a (Bobe et al., , 2010b . Single-nucleotide polymorphisms (SNPs) in the promoter region of genes encoding IL-1b, 6, 8, and 10 may alter the secretion of cytokines (Fishman et al., 1998; Hwang et al., 2002; Reuss et al., 2002; Hacking et al., 2004; Rad et al., 2004) and, as a result, the risk of adenoma recurrence generally or in response to dietary flavonols. Thus, IL SNPs may indicate individuals more likely to benefit from a chemopreventive dietary intervention.
The aim of this study was to examine whether SNPs in the promoter regions of genes encoding IL-1b, 6, 8, and 10 could influence adenoma recurrence alone or in combination with flavonol intake or serum IL concentrations. To our knowledge, this is the first study to investigate the joint effects of IL genotype, serum IL levels, and flavonol intake on adenoma recurrence.
Materials and methods

Study design and population
The Polyp Prevention Trial (PPT) was a large, multicenter, randomized 4-year nutritional intervention trial used to evaluate the effects of promoting a high-fiber, high-fruit and vegetable, low-fat diet on the recurrence of colorectal adenomas. Details of the study have been described elsewhere (Lanza et al., 1996 (Lanza et al., , 2001 Schatzkin et al., 2000) . In brief, study participants had at least one histologically confirmed colorectal adenoma identified by complete colonoscopy in the 6 months before the study entry. Of the 1905 participants who completed the trial by undergoing a colonoscopy at the end of year 4, 958 were in the intervention arm. Our study included 808 participants in the intervention arm with available dietary data for any of the first 3 years of the trial, IL SNP data, and serum from baseline (T0) and from either year 1 (T1) or year 3 (T3). Dietary information and serum samples from T4 were not used because some of these were taken after the final colonoscopy. All lesions were examined for histological features and degree of atypia by two independent pathologists. Recurrence outcomes were defined as having any (n = 318), advanced (Z 1 adenoma of Z 1 cm in size, having at least 25% villous component, or exhibiting high-grade dysplasia; n = 45) or high-risk (Z 1 advanced adenoma or Z 3 pathologically confirmed adenomas; n = 88) adenomas.
Lifestyle and flavonol data
Participants completed an interviewer-administered questionnaire regarding demographics, family history, and use of medication or supplements at baseline (T0) and at each of the annual follow-up visits (T1, T2, T3, T4). A modified food frequency questionnaire (FFQ) eliciting information on the frequency and portion size of 119 food and beverage items consumed over the past 12 months (Block et al., 1990; Caan et al., 1999) was also completed at each of these visits. Trained, certified nutritionists reviewed all FFQs with participants. Using the 2007 US Department of Agriculture flavonoid database that contains flavonol values for 308 food and beverage items (US Department of Agriculture ARS, 2007), 55 of the 119 food and beverage items could be matched with flavonol values, which were provided as concentrations of the individual flavonols -isorhamnetin, kaempferol, myricetin, and quercetin. Flavonol intake was calculated as the sum of isorhamnetin, kaempferol, myricetin, and quercetin, which represent over 99% of dietary flavonol intake (Chun et al., 2007; Bobe et al., 2008) . Compared with 24-h dietary recall and 4-day food record data, the FFQ slightly overestimated fat and underestimated fiber, fruit and vegetable intake and had acceptable correlations of fat (r = 0.63), fiber (r = 0.63), fruit and vegetable (r = 0.72), dry bean (r = 0.76), and other macronutrients and micronutrients (Caan et al., 1999; Lanza et al., 2001) .
Interleukin genotype data
The SNPs in IL-encoding genes were selected based on the following criteria: (i) a reported association between the SNP and colorectal adenoma or cancer (Gunter et al., 2006; Ito et al., 2007; Tsigris et al., 2007; Cacev et al., 2008; Tsilidis et al., 2009), (ii) an association between the SNP and transcriptional activity and serum concentrations of its encoded gene product (Fishman et al., 1998; Hwang et al., 2002; Reuss et al., 2002; Hacking et al., 2004; Rad et al., 2004) and (iii) evidence that flavonols alter the activities of transcription factors of IL-encoding genes (Hungness et al., 2002; Kim et al., 2005; Lee et al., 2008; Kumamoto et al., 2009) and serum concentrations of their gene products (Comalada et al., 2006; Sharma et al., 2007; Okoko and Oruambo, 2009 ). Details of genotyping have been described earlier (Sansbury et al., 2006) . In brief, high-throughput genotyping was carried out by BioServe Biotechnologies Ltd. (Laurel, Maryland, USA) using a two-step PCR process and mass spectrometry (Masscode, Qiagen Genomics, Bothel, Washington, USA; Kokoris et al., 2000) . Call rates for SNPs in IL-encoding genes were as follows: IL-1b -511 C > T (rs16944) 93.5%, IL-6 -174 G > C (rs1800795) 91.8%, IL-8 -251 T > A (rs4073) 92.7%, IL10 -592 C > A (rs1800872) 98.3%, IL10 -819 C > T (rs1800871) 95.0%, and IL-10 -1082 G > A (rs1800896) 95.5%. Quality control consisted of repeated assays of approximately 10% randomly selected samples and the inclusion of blinded controls. The concordance of duplicate samples was above 97%.
Interleukin serum data
Serum concentrations of IL-1b, 6, 8, and 10 at baseline, T1, and T3 were measured by the Clinical Support Laboratory of SAIC Frederick Inc. (Frederick, Maryland, USA) using a commercially available multiplex 96-well enzymelinked immunoabsorbent assay kit (MS6000 Human Pro-Inflammatory 9-Plex Ultra-Sensitive Kit K11007; Meso Scale Diagnostics, Gaithersburg, Maryland, USA) on a Sector Imager 6000 according to the manufacturer's recommendation (Meso Scale Diagnostics). The interassay coefficients of variation were below 15%. test for continuous variables and Fisher's exact test for categorical variables and are shown as medians and interquartile ranges. All SNPs were tested for, and were in agreement with, Hardy-Weinberg equilibrium.
The associations between IL SNPs and their corresponding serum concentrations were evaluated with the Kruskal-Wallis test and multiple linear regression models. Potential confounders, listed in Table 1 , were included in the logistic regression models if the confounder changed the association by 10% or more, was associated with both IL SNPs and their corresponding serum concentrations, and had a w 2 P value of 0.20 or less. Regular nonsteroidal anti-inflammatory drug use was not included in the statistical models because it was not associated with adenoma recurrence in this population (Table 1) (Hartman et al., 2005; Bobe et al., 2010a Bobe et al., , 2010b .
We used logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI) for adenoma recurrence at T4 by IL SNPs using the homozygote of the more frequent allele as the referent category and race, age, and sex as covariates. For linear trend testing, the referent category was the more frequent allele that was scored on an ordinal scale as 0, the heterozygote was scored as 1, and the rare homozygote was scored as 2 (codominant model). For the dominant model, homozygous and heterozygous carriers of the less frequent gene were combined and scored as 1. The IL-10 haplotypes were composed of three polymorphic sites -1082 A/G, -819 C/T, and -592 C/A: IL-10 A-C-C was comprised of -1082 AA, -819 CC, -592 CC (referent haplotype); IL-10 G-C-C was -1082 G, -819 CC, -592 CC; and IL-10 G-T-A was -1082 G, -819 T, -592 A. All comparisons against the no adenoma recurrence group. P values for differences in proportions were calculated using Fisher's exact test. P values for differences in medians were calculated using Wilcoxon rank-sum test. c Family history of colorectal cancer was defined as having Z 1 first-degree relative with colorectal cancer at baseline.
The combined effect of IL genotype and flavonol intake on colorectal adenoma recurrence was evaluated using the median flavonol intake during the first 3 years of the trial as the cut-off point (r median, > median) and carrier status of the rare allele (yes, no). The group with the largest number of advanced adenoma cases was chosen as the referent category consisting of individuals with below median flavonol intake, who carried at least one copy of the less frequent allele. To examine the combined effect of IL genotype and changes in serum IL concentrations, defined as the geometric mean of T1 and T3 minus the baseline values, we used the median IL change as the cut-off point (r median, > median); the referent category was individuals with an increase in IL concentrations, who carried at least one copy of the less frequent allele. Effect modification was evaluated by calculating the cross product interaction terms. All P values corresponded to twosided tests. Differences were considered to be significant at P value of 0.05 or less and borderline significant at P value of 0.10 or less.
Results
At the end of the 4-year trial, 39% of the 808 participants in the intervention arm had one or more adenoma, 11% had a high-risk adenoma, and 6% had an advanced adenoma (Table 1) . Adenoma recurrence was more common in older individuals. Flavonol consumption doubled from 14.6 mg/day at baseline to 29.7 mg/day during the first 3 years of the trial (Bobe et al., 2010a) . Individuals with high-risk and advanced adenoma recurrence ate more calories from fat and consumed less fruits and vegetables, fiber, flavonols, and dry beans during the first 3 years of the study. High-risk adenoma recurrence was also positively associated with BMI.
The SNPs in genes encoding IL-1b, 6, 8, and 10 were not associated with serum concentrations of their gene product; however, baseline serum IL-10 concentrations tended to linearly increase with IL-10 -819 T allele copy number (P for trend = 0.07) and IL-10 G-T-A haplotype (P for trend = 0.06; Table 2 ). Furthermore, an exploratory analysis suggested that IL SNPs may alter serum concentrations of ILs other than their own gene product, for example, IL-1b -511 SNP was associated with serum IL-8, IL-8 -251 SNP was associated with serum IL-6, and IL-10 -592 SNP was associated with serum IL-1b (results not shown). Alone, the examined IL SNPs did not predict risk of adenoma recurrence in either a dominant or codominant model, except that the IL-1b -511T and the IL-6 -174 G alleles may have a protective effect against high-risk (OR = 0.62, 95% CI: 0.38-1.01, P = 0.05 for the dominant model) and advanced adenoma recurrence (P for trend = 0.07 for the codominant model), respectively (Table 3) .
We investigated whether IL SNPs in combination with changes in serum IL concentrations during the trial may affect the risk of adenoma recurrence (Table 4 ). The analysis is based on the widespread assumption that SNPs will only be able to affect adenoma risk if they are functionally significant, meaning that they can alter secretion of their gene products, which is in this case IL secretion. An increase in serum IL-10 resulted in a greater risk of high-risk adenoma recurrence when combined with IL-10 -592 CC (OR = 2.23, 95% CI: 1.07-4.66, P = 0.03 compared with individuals carrying the A allele; P interaction = 0.03) or with IL-10 -819 CC (OR = 2.18, 95% CI: 1.05-4.51, P = 0.04; compared with individuals carrying the T allele; P interaction = 0.05). In addition, individuals with the combination of IL-6 -174 GG and a decrease in serum IL-6 had a statistically significantly lower risk of advanced adenoma recurrence compared with those with each of the other three combinations of IL-6 -174 SNP and serum IL-6 change (P interaction = 0.06).
When IL SNPs were analyzed with flavonol intake (Table 5) , individuals who carried IL-6 -174 GG and had above median flavonol consumption had a statistically significantly lower risk of advanced adenoma recurrence compared with each of the other three combinations of IL-6 -174 SNP and flavonol intake; however, the interaction term was, in contrast to the main effects for IL-6 SNP (P = 0.05) and flavonol intake (P = 0.04), not significant (P = 0.16). Furthermore, those with above median flavonol intake combined with the IL-1b -511 T allele (OR = 0.32, 95% CI: 0.11-0.94, P = 0.04), IL-10 -592 A allele (OR = 0.17, 95% CI: 0.04-0.80, P = 0.02), or IL-10 -819 T allele (OR = 0.18, 95% CI: 0.04-0.84, P = 0.03) had a lower risk of advanced adenoma recurrence compared with individuals of the same genotype and below or median flavonol intake (Table 5 ).
Discussion
Our objective was to examine whether SNPs in the promoter region of genes encoding IL-1b, 6, 8, and 10 may influence, alone or in combination with flavonol intake or serum IL concentrations, adenoma recurrence. Overall, we found no statistically significant associations < 25, 25.0-29.9 , Z 30 kg/m 2 ), race (Caucasian, non-Caucasian), and current smoking status during the first 3 trial years. An increase in IL-10 concentrations was associated with a significantly greater risk of high-risk adenoma recurrence in individuals homozygous with IL-10 -592 C and IL-10 -819 C compared with individuals carrying the IL-10 -592 A and IL-10 -819 T allele, respectively. The combination of decreased IL-6 concentrations and IL-6 -174 GG had a significantly lower risk estimate of advanced adenoma recurrence compared with the other three combinations. In individuals with IL-10 -592 CC, IL-10 -819 CC, and IL-10 -1082 AA/AG, a decrease in IL-10 concentration had a significantly lower risk estimate of advanced adenoma recurrence than an increase in IL-10 concentration. The interaction between change in IL-10 concentration and IL-10 haplotype on the risk of advanced adenoma recurrence could not be computed because no individual with a decrease in IL-10 and IL-10 AA-CC-CC haplotype had advanced adenoma recurrence.
between the SNPs in IL-encoding genes and serum concentrations of their gene products or colorectal adenoma recurrence in the intervention arm of the PPT, suggesting that IL SNPs alone may not predict adenoma recurrence. However, individuals homozygous for IL-10 -592 C or IL-10 -891 C had an elevated risk of high-risk adenoma recurrence when their serum IL-10 concentrations increased during the trial. In addition, IL-6 -174 GG in combination with above median flavonol consumption or with decreases in serum IL-6 concentrations during the trial resulted in a reduced risk of advanced ade-noma recurrence. Our results suggest that IL SNPs, in combination with flavonol intake or serum IL concentrations, may influence adenoma recurrence.
Growing evidence suggests that chronic inflammation, involving upregulation of both pro-inflammatory and anti-inflammatory ILs, may be an important target for colorectal cancer prevention (Lin and Karin, 2007) . Gene and protein expression of IL-1b, 6, and 8 is elevated in the tumor microenvironment compared with normal colon tissue (Schetter et al., 2009) , often indicated by an increase < 25, 25.0-29.9 , Z 30 kg/m 2 ), and average energy intake (continuous) during the first 3 trial years. Individuals who consumed a flavonol-rich diet and carried IL-6 -174 GG had a significantly lower risk estimate of advanced adenoma recurrence compared with each of the other three combinations. Individuals that consumed a flavonol-rich diet and carried the IL-1b -511T, IL-10 -592 A, or IL-10 -819 T allele had a significantly lower risk estimate of advanced adenoma recurrence than individuals with lower flavonol intake. In individuals with IL-10 AA-CC-CC, a higher flavonol intake was associated with a decreased risk of advanced adenoma recurrence compared with a lower flavonol intake. The combination of high flavonol intake and IL-1b -511 TT/TC had a significantly lower risk estimate of highrisk adenoma recurrence than the combination of low flavonol intake and IL-1b -511 CC. b Flavonol intake below or above the median of the mean intake during the first 3 trial years (T1,2,3). c Composed of three polymorphic sites: -1082 AA/G, -819 CC/T and -592 CC/A. in serum IL-1b, 6, and 10 concentrations in individuals with advanced adenoma recurrence (Bobe et al., 2010a (Bobe et al., , 2010b . Thus, functional SNPs in the promoter regions of genes encoding IL-1b, 6, 8, and 10 may alter secretion of ILs (Fishman et al., 1998; Hwang et al., 2002; Reuss et al., 2002; Hacking et al., 2004; Rad et al., 2004) and, as a result, cancer risk (Yang et al., 2006) . Consistent with earlier studies (Sansbury et al., 2006; Hubner et al., 2007) , we found IL SNPs alone did not predict adenoma recurrence. In earlier studies, the direction of associations between IL-1b, 6, 8, and 10 SNPs and colorectal adenoma (Gunter et al., 2006) or cancer (Ito et al., 2007; Slattery et al., 2007; Tsigris et al., 2007; Zumkeller et al., 2007; Cacev et al., 2008; Tsilidis et al., 2009; Vasku et al., 2009) have been inconsistent.
SNPs in the promoter regions of ILs are one of many mechanisms by which IL secretion, inflammation, and further downstream colorectal neoplastic changes can be altered. Besides SNPs, IL gene and protein expression can be changed by epigenetic events, abundance and distribution of nuclear transcription factors, micro RNAs, the half-life of mRNA transcripts, and other posttranscriptional mechanisms (Vanden Berghe et al., 1999; Schetter et al., 2010) . Environmental factors, inflammation status, and IL induction model modify IL gene and protein expression (Fishman et al., 1998; Hwang et al., 2002; Reuss et al., 2002; Hacking et al., 2004; Rad et al., 2004) . Serum IL concentration measurements may not necessarily indicate true physiological IL bioavailability because serum IL concentrations are generally low, have a limited dynamic range, diurnal variations, and short halflives, and lack specificity for location, strength, and type of inflammation. Furthermore, the influence of IL SNPs on inflammation and cancer may be more complex than a direct association between IL SNPs and serum concentrations of their gene product (in our exploratory analysis, IL SNPs were associated with serum concentrations of ILs other than their gene product).
An increase in serum IL concentrations in combination with a specific IL genotype may indicate increased risk of adenoma recurrence. In this study, individuals with IL-10 -592 CC or IL-10 -891 CC had the greatest risk of highrisk adenoma recurrence when their serum IL-10 concentrations increased during the trial. The role of IL-10 in colorectal carcinogenesis is complex (Lin and Karin, 2007) : IL-10 may promote or inhibit colorectal neoplastic changes depending on environmental factors such as the intestinal microbial population in the host. Elevated serum IL-10 may indicate downregulation or upregulation of inflammation, as IL-10 secretion is upregulated in response to increased inflammation. Smoking, nuclear transcription factors, BMI, sex, regular nonsteroidal anti-inflammatory drug use, and other IL-10 SNPS may partly determine which IL-10 allele upregulates IL-10 gene and protein expression more strongly (Crawley et al., 1999; Rees et al., 2002; Reuss et al., 2002; Temple et al., 2003) . This may explain why IL-10 SNPs are not consistently associated with increased risk of colorectal cancer (Tsigris et al., 2007; Cacev et al., 2008; Tsilidis et al., 2009 ) indicating a complex interaction between environmental factors, IL-10 SNPs, inflammation, and colorectal cancer. Host genetics may partly predict whether dietary bioactive compounds have chemopreventive properties. Part of the chemoprotective effect of flavonols may involve attenuating secretion of proinflammatory compounds (Kim et al., 2005; Lee et al., 2008; Okoko and Oruambo, 2009) , which, in part, may be regulated by SNPs in the promoter region of ILs. In support of our hypothesis, individuals with IL-6 -174 GG, in combination with higher flavonol intake, had a decreased risk of advanced adenoma recurrence compared with other combinations of flavonol consumption and IL-6 -174 SNP, although this observation is based on very few cases. The role of IL-6 -174 SNP on prevention of adenoma recurrence is not surprising given that the IL-6 -174 SNP is close to binding sites of IL-6 transcription factors (Vanden Berghe et al., 1999; Terry et al., 2000) that can be modified by flavonols (Lee et al., 2008; Hungness et al., 2002) and the fact that high flavonol intake (> 30 mg/day) decreased serum IL-6 concentrations and high risk and advanced adenoma recurrence in the PPT (Bobe et al., 2010a) .
A major strength of this study is the information on adenomas from complete colonoscopies performed at baseline, T1, and T4, and histologic characteristics noted by two pathologists independently, decreasing the risk of misclassification. Another strength is that the dietary questionnaire, developed specifically for this study, focused on fruit and vegetable consumption (Block et al., 1990; Caan et al., 1999; Lanza et al., 2001) , and the questionnaire was linked to the recently released validated US Department of Agriculture flavonoid database (US Department of Agriculture ARS, 2007). Furthermore, registered dieticians reviewed the completed dietary questionnaires with participants, which further improved the accuracy of the questionnaire (Caan et al., 1999; Lanza et al., 2001) . Other strengths of this study included the prospective and repeated collection of both the serum and dietary data.
There are, however, several limitations to our study. Our study findings may not apply to the general population because all participants had a history of adenomas, a relative healthy diet, and most engaged in a healthpromoting lifestyle. The observed associations could be because of chance, multiple comparisons, or due to IL SNP being in linkage disequilibrium with other functional or regulatory SNPs (Hacking et al., 2004) . Dietary measurement error related to the dietary assessment technique cannot be ruled out and could lead to attenuated risk estimates. The dietary intervention of the trial was not specific to flavonol consumption; therefore, observed changes could be the result of other chemoprotective compounds known to decrease colorectal adenoma risk, such as dry beans, fiber, and folate. However, none of the other chemopreventive compounds had a significant effect on adenoma recurrence in the PPT, except for dry beans, which have high flavonol content. Furthermore, we had limited statistical power for testing interactions between IL SNPs, flavonol intake, serum IL concentrations, and advanced adenoma recurrence. However, this is, to our knowledge, the first study to investigate the joint effects of IL genotype, serum IL levels, and flavonol intake on adenoma recurrence.
In conclusion, our results suggest that IL SNPs, in combination with a flavonol-rich diet or with a decrease in serum IL concentrations, may decrease the risk of adenoma recurrence. Further studies are needed to examine the importance and biological role of IL SNPs for chemopreventive strategies to identify individuals more likely to benefit from chemopreventive compounds such as flavonols.
